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Summary 
Cytokines, released  in and around pancreatic islets during insulitis, have  been proposed to participate 
in B-cell destruction associated with autoimmune diabetes. In this study we have evaluated the 
hypothesis that local release of the cytokine interleukin 1 (IL-1) by nonendocrine cells of the 
islet induce the expression of inducible nitric oxide synthase (iNOS)  by 3  cells which results 
in the inhibition of 3 cell function. Treatment of rat islets with a combination of tumor necrosis 
factor (TNF) and lipopolysaccharide (LPS), conditions known to activate macrophages, stimulate 
the expression ofiNOS and the formation of nitrite. Although TNF + LPS induce iNOS expression 
and inhibit  insulin  secretion by intact islets, this combination does not induce the expression 
of iNOS by 3 or o~ cells purified by fluorescence activated cell sorting (Facs). In contrast,  IL-13 
induces the expression of iNOS and also inhibits insulin secretion by both intact islets and Facs- 
purified 3  cells, whereas TNF+LPS have no inhibitory effects on insulin secretion by purified 
3  cells. Evidence suggests that TNF+LPS inhibit insulin  secretion from islets by stimulating 
the release of IL-1 which subsequently induces the expression of iNOS by 3  cells. The IL-1 
receptor antagonist protein completely prevents TNF+ LPS-induced inhibition of insulin secretion 
and attenuates nitrite formation from islets, and neutralization  of IL-1 with antisera specific for 
IL-  1  oL and IL-  13 attenuates TNF + LPS-induced nitrite formation by islet  s. Immunohistochemical 
localization  of iNOS and insulin confirm that TNF+LPS induce the expression of iNOS by 
islet 3 cells, and that a small percentage of noninsulin-containing  cells also express iNOS. Local 
release of IL-1 within islets appears to be required for TNF+LPS-induced inhibition  of insulin 
secretion because TNF+LPS do not stimulate nitrite formation from islets physically separated 
into individual cells. These findings provide the first evidence  that a limited number of nonendocrine 
cells can release sufficient quantities of IL-1 in islets to induce iNOS expression and inhibit the 
function of the 3 cell, which is selectively  destroyed  during the development of autoimmune diabetes. 
I 
nsulin-dependent diabetes mellitus (IDDM) is an autoim- 
mune disease  characterized  by a local inflammatory reaction 
in and around islets that is followed by selective destruction 
of the insulin-secreting 3 cell. Macrophages and monocytes 
comprise the early islet insulitis,  followed by the presence 
ofT cells (1-3). It has been proposed that the cytokine IL-1, 
released during islet insulitis, participates in 3  cell destruc- 
tion (4-6). Treatment of rat islets with IL-1 results in a time- 
and concentration-dependent inhibition of insulin secretion 
that is followed by islet degeneration (7-10). IL-13 inhibits 
insulin secretion by inducing the expression of inducible ni- 
tric oxide  synthase  (iNOS)  1 and the production of nitric 
oxide (11-13). Inhibitors  of iNOS, NG-monomethyl-t-argi  - 
1 Abbreviations used in this paper: iNOS, inducible nitric oxide synthase; 
IRAP, IL-1 receptor  antagonist  protein; KRB, Kregs-Ringer  bicarbonate 
buffer; NOD, nonobese  diabetic; NMMA, NC-monomethyl-t-arginine. 
nine (NMMA), aminoguanidine, and nitro-t-arginine methyl- 
ester, prevent both the inhibitory effects of cytokines on in- 
sulin secretion, and cytokine-induced  nitric oxide formation 
by rat, mouse, and human islets (11, 14-17). IL-13 has been 
shown to induce the accumulation of iNOS mRNA in two 
different insulinoma  cell lines (18, 20). 
In vivo evidence suggests that nitric oxide participates in 
the development of autoimmune diabetes. Lukic et al. (21) 
have shown that NMMA prevents the development of dia- 
betes in male mice injected for 5 d with streptozotocin.  In 
this model,  streptozotocin  produces an inflammatory reac- 
tion characterized by the presence of lymphocytes and mac- 
rophages followed by 3 cell necrosis. In the nonobese spon- 
taneous diabetic mouse (NOD), the transfer of spleen cells 
from a diabetic female NOD mouse to an irradiated nondia- 
betic male NOD mouse induces diabetes 11-13 d after transfer. 
We have shown that islets isolated from recipient male NOD 
mice produce nitric oxide in a time-dependent fashion that 
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phages (22). Treatment of recipient male NOD mice with 
two daily injections of aminoguanidine delays the develop- 
ment of diabetes in this model by 7-10 d (22). Also, the pres- 
ence ofiNOS mRNA has recently been demonstrated in and 
around islets  of prediabetic BB rats  (23). 
Islets of Langerhans contain a heterogeneous population 
of both endocrine (/3, or, 6, and polypeptide secreting cells) 
and nonendocrine cells (macrophages, endothelial cells, den- 
dritic cells,  and fibroblasts).  The cellular sources of iNOS 
in animal models of diabetes are unknown, but in vitro treat- 
ment of purified populations of/3 cells with IL-I~ stimu- 
lates  the accumulation of nitrite and cGMP,  whereas this 
cytokine does not induce nitric oxide formation by purified 
populations of ot cells (24). IL-1B-induced expression of iNOS 
by islet/3 cells has recently been confirmed by immunopre- 
cipitation using antiserum  specific  for mouse macrophage 
iNOS (20). 
/~ cell destruction associated with autoimmune diabetes 
is characterized by an early peri-insulitis in which lympho- 
cytes and macrophages are located on the periphery of islets. 
This peri-insulitis is followed by invasion of these immune 
cells into islets (25). Under these conditions, cytokine release 
may have marked effects on islet function. In this study, con- 
ditions have been found that stimulate the release of IL-1 in 
islets.  Evidence is  presented which  shows  that  cytokines 
released in islets by nonendocrine cells induce the expression 
of iNOS and inhibit insulin secretion by islet/3 cells. These 
results provide the first experimental evidence demonstrating 
that local release of cytokines in islets can directly modulate 
B cell function. 
Materials  and Methods 
Materials and Antiserum.  CMtLL-1066  tissue culture medium, 
fetal  bovine serum, and glutamine were obtained from GIBCO BILL 
(Gaithersburg, MD). Collagenase, human recombinant TNF-c~, 
and human recombinant IFN-3/were from Boehringer Mannheim 
(indianapolis, IN). NMMA acetate was from Calbiochem-Novabio- 
chem Corp.,  (La Jolla, CA),  and recombinant human Ibll3 was 
purchased from Cistron Biotechnology, Inc. (Pine Brook,  NJ). 
[3sS]-trans-labeled methionine  (1,117 Ci/mmol) was  from ICN 
(Costa Mesa, CA).  Rabbit  antiserum  specific for mouse macro- 
phage iNOS used for immunohistochemistry and rabbit antiserum 
specific for the COOH-terminal 27 amino acids of mouse macro- 
phage iNOS used for immunoprecipitation  studies were kind gifts 
from Drs. Michael Marletta (University of Michigan, Ann Arbor, 
MI) and Thomas Misko (Monsanto Corporate Research, St. Louis, 
MO), respectively. Hamster anti-mouse IL-I~ (B122) and hamster 
anti-mouse  IL-lcx (ALF) were gifts from Dr.  Robert Schreiber 
(Washington University School of Medicine). Human and mouse 
recombinant IL-1 receptor antagonist proteins (IILAP) were gifts 
from Dr. Charles Hall (Upjohn,  Kalamazoo, MI). Indocarbocya- 
nine (CY3)-conjugated donkey anti-rabbit,  and FITC-conjugated 
donkey anti-guinea  pig antisera were from Jackson Immuno Re- 
search (West Grove, PA). All other chemicals were from commer- 
cially available sources. 
Islet Isolation and Culture.  Islets  were isolated from male Sprague- 
Dawley rats (200-250 g; Sasco, O'FaUon, MO) by collagenase  diges- 
tion as described previously (26). Islets were cultured  overnight 
in an atmosphere of 95% air and 5% CO2 in complete CMRL- 
1066 tissue culture medium (2 mM L-glutamine, 10% heat-inac- 
tivated fetal bovine serum,  100 U/ml penicillin, and 100/~g/ml 
streptomycin) before the start of experiments. Experiments were 
initiated by the addition of cytokines and endotoxin, 5 U/ml Ibl/3, 
150 U/ml IFN-% 0.7 nM (240 U/ml) TNF, 10 #g/ml LPS, or 
0.5 mM NMMA, and the islets were then incubated for the indi- 
cated periods of time. In some experiments islets were pretreated 
with either human or mouse recombinant IRAP (1/~g/ml) or an- 
tibodies against IL-lct and IL-1B (1 #g/ml for both antisera) for 
1 h before the addition of cytokines. 
Purification of ~  and ot Cells by Fluorescence-activated Cell Sorting 
(Facs).  Islets  isolated from 12 male Sprague-Dawley  rats were cul- 
tured overnight ('-2,500 islets/2.5 ml) in complete CMR.L-1066 
media in an atmosphere of 95% air and 5% CO2. Islets were dis- 
persed into individual cells  by treatment with dispase (0.33 mg/ml) 
in Ca  z+ and Mg  z§ flee Hank's solution (27) at 31~  for 15 rain 
(28). The dispersed islet cells were incubated for 45-60 rain in com- 
plete CMRL-1066 media at 37~  and then purified by the method 
of Pipeleers et al. (29) using an Epics 733 flow cytometer (Coulter 
Corp.,  Hialeah, FL). The cells were illuminated at 488 nm and 
emission was monitored at 515-535 nm. The sorting process  yields 
a 90-95% population  of/3 cells, and an 80-85% population of 
ct cells. The ct cell population also contains some ~ and B cells (28). 
Glucose-stimulated Insulin Secretion by Islets.  After treatment with 
cytokines, islets were washed three times in Krebs-Ringer bicar- 
bonate  buffer  (KRB;  25  mM  Hepes,  115  mM  NaC1, 24 mM 
NaHCO3,  5 mM KC1, 2.5 mM CaC12, and 1 mM MgCI2, pH 
7.4,  containing  3 mM D-glucose, and 0.1%  BSA). Islets were 
counted (20 islets/tube) into 10 x  75 mm siliconized borosilicate 
tubes and preincubated for 30 min  at 37~  with  shaking in a 
Dubnoff water bath in an atmosphere of 95% air and 5% CO2. 
The KRB buffer was then replaced with fresh KRB buffer sup- 
plemented with either 3 or 20 mM D-glucose and the incubation 
continued for 30 min.  The supernatant was withdrawn  and in- 
sulin content was determined by RIA. 
Glucose-induced Insulin Secretion  from Facs-tmrified  fl Cells.  Purified 
/3 cells pretreated for 18 h in complete CMR.b1066, or complete 
CMRL-1066 containing the indicated cytokines, LPS and NMMA, 
were washed three times with KRB containing 3 mM D-glucose 
and 0.1% BSA. ~ cells were then aliquoted into 96-well microtiter 
plates (15,000 cells/100/~1 of KRB containing 3 mM D-glucose 
and 0.1% BSA). Insulin secretion was initiated by the addition of 
an equal volume of KRB containing either 3 mM D-glucose or 
37 mM D-glucose plus 10 mM theophylline (final concentration, 
20 mM glucose and 5 mM theophylline). The phosphodiesterase 
inhibitor theophylline was included to elevate cAMP levels  which 
are required for glucose-stimulated insulin secretion from purified 
cells (29, 30). Cells were incubated for 3 h in an atmosphere 
of 95% air, 5% CO2 at 37~  After the incubation,  cells were 
pelleted by centrifugation (200 g for 10 min), and the supernatant 
was aspirated and analyzed for insulin by RIA. 
Immunoprecipitation of iNOS.  iNOS was immunoprecipitated 
using a modification (31) of methods described previously (32). In 
brief, islets (100) or purified/3 or t~ cells (100,000 cells) were cul- 
tured  with the indicated cytokines and LPS for 5 h  in MEM 
methionine-deficient media (9 parts MEM without methionine/1 
part MEM containing methionine),  300 #Ci of [3SS]methionine 
trans-label was added and the islets were incubated for an addi- 
tional 13 h at 37~  iNOS was immunoprecipitated using rabbit 
anti-iNOS  (1:750 dilution)  antiserum  specific for the COOH- 
terminal 27 amino acids of mouse macrophage iNOS.  Immuno- 
precipitates were analyzed on 8% SDS-polyacrylamide gels (33) 
and visualized by fluorography. 
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50-gl portions of culture media with 50 gl of the Griess reagent 
(34), and the absorbance at 540 was measured using a Multiskan 
(model MCC/340;  Titertek, Elfab Oy,  Finland)  plate reader.  In 
experiments comparing the effects of IL-1~8 and TNF+ LPS on ni- 
trate formation by intact islets and islet cells, islets were dispersed 
into single  cells as described above and cultured overnight. The 
cells were then washed three times with complete CMRL-1066 and 
added  to 24-well  microtiter plates  at a concentration of 100,000 
cells/400/~1  of the same medium.  Islets  (90/400 #1 of complete 
CMRL-1066) were counted into the same plate and the experiments 
were initiated by the addition of IRAP followed by the addition 
of cytokines and LPS as described above. The supernatant was iso- 
lated by centrifugation and used for nitrite determinations. 
Immunohistochemistry.  Immunohistochemistry was performed 
as described previously for sequential double staining (35). In brief, 
isolated  islets  were either untreated or incubated with the indi- 
cated concentrations of IL-1/3, TNF, LPS, and IRAP for 24 h, iso- 
lated, washed three times with 0.1 M PBS, pH 7.4, and then fixed 
in 1 ml of 4% paraformaldehyde in 0.1 M phosphate buffer, pH 
7.4, overnight at 4~  Islets  were then cryopreserved overnight 
in 0.1 M phosphate buffer, pH 7.4, containing 10% sucrose, frozen, 
and then cut into 10-gm sections.  Sections  were incubated over- 
night at 4~  with the primary antisera at the following dilutions: 
rabbit anti-iNOS prepared against mouse macrophage iNOS, 1:500; 
guinea pig anti-human insulin,  1:500. Slides were washed and then 
incubated  for 2  h  with  secondary antiserum,  CY3-conjugated 
donkey anti-rabbit, and FITC-conjugated donkey anti-guinea pig, 
at dilutions of 1:200. Staining was visualized by fluorescent mi- 
croscopy where insulin- and iNOS-containing cells stain green and 
red, respectively. 
Statistics.  Statistical  comparisons were made between groups 
using a one-way analysis of variance. Significant differences (p <0.05) 
were evaluated  using a Scheffe's F-test  posthoc analysis. 
Results 
Effects of Cytokines  and LPS on iNOS Expression by Intact 
Islets and Facs-purified  ~ and cr Cells.  The effects ofcytokines 
and endotoxin on iNOS expression by islets and Facs-purified 
populations of both/3 and c~ ceUs are shown in Fig.  1, a and 
b, and Table 1. IL-1B stimulates the expression of iNOS by 
both intact islets  and purified/3 cells, but does not induce 
iNOS expression in purified populations of o~ cells. Individ- 
ually, TNF, IFN-'y, or LPS stimulate low levels of iNOS ex- 
pression by islets but do not induce the expression of iNOS 
by purified/3 cells (Table 1). In combination, TNF + LPS stimu- 
late iNOS expression to a level that is 50%  lower than the 
level induced by IL-1/3 in islets.  TNF+LPS  do not induce 
the expression of iNOS by purified populations  of B  or a 
cells.  In combination with TNF,  IFN-'y induces iNOS  ex- 
pression to a level that is 47%  of that observed with IL-1/$ 
in islets.  IFN-'f  also  appears  to reduce the level of IL-113- 
induced iNOS  expression (45%  inhibition)  by both intact 
islets and purified 3  cells.  These findings  show that  IL-113 
stimulates the expression ofiNOS by the ~/cell. The combi- 
nations of TNF+LPS and IFN-  3, +TNF also induce the ex- 
pression of iNOS by intact islets,  but this does not appear 
to be a direct effect of these cytokines and endotoxin on 
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Figure  1.  Effects  of  cytokines  and endotoxin  on 
iNOS expression  by rat islets and Facs-purified 
and ~  cells. Intact islets (a), and Facs-purified  ~/ 
and c~ cells (b) were incubated  for 5 h with 5 U/ml 
1I.-1/3, 150 U/ml IFN-% 0.7 nM TNF, and 10 
#g/ml LPS alone or in combination as indicated. 
[3sS]Methionine  was added and the islets and cells 
were incubated for an additional 13 h. iNOS was 
immunoprecipitated using antiserum specific  for 
the COOH-termina127  amino acids of  mouse  mac- 
rophage  iNOS. Immunoprecipitates  were  separated 
on 8% SDS-polyacrylamide  gels and visualized  by 
fluorography. Results are representative  of two to 
three individual experiments. Table  1.  Effects of Cytokines and LPS on iNOS Expression 
by Islets and Purified fl Cells 
Optical  density 
Treatment  (IL-l-induced iNOS) 
% 
Islets 
Control  0 
IL-1  100 
TNF  16  _+  5 
IFN  11  +  7 
IL-I+TNF  101  +_  17 
IL-1 +IFN  59  _+  8 
TNF + IFN  47  +_  18 
IL-1 + TNF + IFN  53  -+  16 
LPS  14  _+  4 
LPS+TNF  50  +  9 
Purified 13 cells 
Control  0 
IL-1  100 
TNF  0 
IFN  3  -+ 4 
IL-I+ TNF  103  +  7 
LPS  9  _+  7 
IL-1 + IFN  45  _+  16 
TNF + LPS  0 
Densitometry  was performed  on immunoprecipitation  data shown in Fig. 
1. The level  ofiNOS expression  after  treatment  with IL-1  was set at 100%. 
Results are the average + SEM from two experiments  with two repli- 
cates/condition. 
or ot cells. These combinations of cytokines and endotoxin 
(TNF+LPS, IFN-7 +TNF) are known to activate macrophages 
to release cytokines (IL-1 and TNF) and to produce nitric 
oxide (36-39), suggesting that the resident islet macrophage 
is  a source of iNOS. 
Effects of  lL-lfl and TNF+LPS on Insulin Secretion by Islets. 
The effects of nitric oxide production on insulin secretion 
by islets were examined under conditions that induce iNOS 
expression by the/5 cell (IL-1/3) or conditions that induce 
the highest level of iNOS expression by nonendocrine islet 
cells (TNF+LPS, see Table 1). As shown in Fig. 2, treatment 
of rat islets for 18 h with IL-1/3 completely inhibits glucose- 
stimulated insulin secretion, and this effect is attenuated by 
0.5 mM NMMA. Under these conditions, IL-1/3 stimulates 
a threefold increase in nitrite release from the same islets used 
for insulin secretion, and this increase is completely prevented 
by NMMA. TNF+ LPS treatment of islets for 18 h inhibits 
glucose-stimulated insulin secretion by 40o7o, and this inhi- 
bition is completely attenuated by NMMA. TNF+LPS in- 
duce a 50~  increase  in the release of nitrite from the same 
islets  used for insulin secretion, and this is also completely 
prevented by NMMA. Our previous studies (15) have shown 
that NMMA  completely prevents the inhibitory effects of 
IL-1/3 on insulin secretion by rat islets. The lack of complete 
protection in these studies appears to result from the produc- 
tion of nitric oxide during the insulin secretion portion of 
these experiments (See Materials and Methods).  When NMMA 
is included in the buffers used for insulin secretion (KRB 
containing 3 or 20 mM glucose and 0.1% BSA),  complete 
prevention of the inhibitory effects of IL-1/3 are observed (data 
not shown). 
Effects of lLqfl and TNF+LPS on Insulin Secretion by Facs- 
purified [~ Cells.  The effects  of IL-1/3  and  TNF+LPS on 
glucose-stimulated insulin secretion and nitrite formation by 
Facs-purified/3 cells are shown in Fig. 3, a and b. Treatment 
of purified/3 cells with IL-1/3 for 18 h results in a 70% inhi- 
bition of insulin secretion that is attenuated by NMMA. This 
inhibition of insulin secretion correlates with a 10-fold  in- 
crease in nitrite release from the same/3 cells used for secre- 
tion,  and  the release  of nitrite is completely prevented by 
NMMA.  TNF+LPS have no inhibitory effects  on insulin 
secretion, and do not induce the formation of  nitrite by purified 
/3 cells. As shown in Fig. 1 b this combination does not in- 
duce iNOS expression by purified/3 cells. The inhibitory effects 
of TNF+ LPS on glucose-stimulated insulin secretion by islets 
suggest that either TNF+ LPS induce the expression of iNOS 
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Figure  2.  Effects  of IDIB and 
TNF+LPS on glucose-stimulated 
insulin secretion  by islets. Islets  were 
incubated  for 18 h with or without 
5 U/ml II,-1/3, 0.7 nM TNF, 10 
#g/ml LPS, and 0.5 mM NMMA 
as  indicated. Islets were isolated 
for insulin secretion  (a) and nitrite 
formation was determined on the 
incubation media (b). Results are 
the average _+  SEM of four indi- 
vidual experiments  containing  three 
replicates  per condition.  Statistically 
significant inhibition  of insulin se- 
cretion and  nitrite formation as 
compared  with controls  are indicated 
(*, p <0.001; and **, p <0.05). Control 
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TNF+LPS 
IL-I+NMM,a 
TNF+LPS 
+NMIVI,4 
3G  [] 
2~+~  ￿9 
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Insulin Secretion (ng/2000 ~cells-3 h) 
by nonendocrine islet cells (macrophages or endothelial cells) 
and the resulting production of nitric oxide inhibits/3 cell 
function, or that TNF+ LPS stimulate the release  of  cytokines 
that induce iNOS expression by/3 cells. 
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Figure  4.  Effects of IRAP on IL-1/3 and TNF+LPS-induced inhibi- 
tion of glucose-stimulated insulin secretion by islets. Islets were pretreated 
for 1 h with 1/~g/ml human recombinant IKAP. The islets were then 
incubated for an additional 24 h with 5 U/ml Ibl13, or 0.7 nM TNF 
and 10 #g/ml LPS as indicated. After the 24-h incubation, the culture 
media were removed for nitrite determination (b) and insulin secretion 
was examined on the islets (a).  Results are the average  _+ SEM of an in- 
dividual experiment containing three replicates per condition, and are rep- 
resentative of three individual experiments. 
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Figure  3.  Effects  of Ibl~/ and 
TNF+LPS  on  glucose-stimulated 
insulin secretion by Facs-purified/3 
cells. ~3 cells purified by Facs were 
incubated for 18 h with 5 U/ml IL- 
1/3, 0.7 nM TNF,  10 #g/ml LPS, 
or 0.5 mM NMMA as indicated. 
The cells were then isolated for in- 
sulin secretion  (a) and nitrite for- 
mation was determined on the cul- 
ture supernatant (b). Results are the 
average  _+  SEM of two individual 
experiments containing four repli- 
cates  per  condition.  Statistically 
significant  inhibition  of  insulin 
secretion and nitrite formation as 
compared with controls are indi- 
cated (*, p  <0.001). 
IRAP Prevents TNF + LPS-induced Inhibition of Insulin Secre- 
tion  by Intact Islets.  The effects of IRAP on TNF+LPS- 
induced inhibition of insulin secretion are shown in Fig. 4 
a.  After  a  24-h  incubation,  TNF+LPS  inhibit  glucose- 
stimulated insulin secretion by 70%, and this inhibitory effect 
is completely prevented by coincubation of islets with 1 #g/ml 
IRAP in addition to TNF+LPS. Incubation of islets for 24 
h with IL-1/3 results in complete inhibition of insulin secre- 
tion that is also prevented by IRAP.  The effects of IRAP 
on TNF+LPS- and IL-1/3-induced  nitrite formation are shown 
in Fig. 4 b. IL-1/3 induces a 4.3-fold increase and TNF+LPS 
induce a 3.3-fold increase in the release of nitrite from the 
same islets used for insulin secretion. IL-1/3-induced nitrite 
formation is completely prevented by IRAP, whereas TNF+ 
LPS-induced nitrite formation is significantly attenuated by 
IRAP. These findings suggest that TNF+ LPS stimulate IL-1 
release, and that IL-1 then induces the expression of iNOS 
by the/3 cell. IRAP does not completely prevent TNF+LPS- 
induced nitrite formation by islets, suggesting that TNF+ LPS 
induce the formation of nitric oxide by islets independent 
of IL-1 release. The higher levels of TNF+LPS-induced ni- 
trite production and inhibition of insulin secretion observed 
in Fig. 4 compared with Fig. 2 is believed to reflect different 
incubation  times of 24 and 18 h, respectively. 
Table  2.  Antibodies  to IL-Icr and IL-1/3  Inhibit 
TNF + LPS-induced Nitrite Formation by Rat Islets 
Conditions  Nitrite  (pmol/Islet) 
Control  11.1  _+  2.4 
LPS + TNF  26.8  -+  2.4 
LPS + TNF + anti-IL-1  15.9  _+  1.7" 
Rat islets (70/200 #1 of complete CMRL-1066) were pretreated for 1 h 
with 1 #g/ml of both anti-IL-lc~ and anti-IL-1B antiserum.  TNF (0.7 nM) 
and LPS (10 #g/ml) were added and the islets were cultured for an addi- 
tional 24 h. The medium was then removed for nitrite determinations. 
Results are the average  _+  SEM of three individual experiments contain- 
ing two to three replicates/condition. Statistically  significant  inhibition 
of TNF + LPS-induced nitrite formation is as indicated (*p  =  0.002). ""  30 
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Figure 6.  Effects  of IRAP on IL-13- and TNF+LPS-induced nitrite 
formation by intact islets and dispersed islet cells. Islets or dispersed islet 
cells were incubated for 24 h with 5 U/ml IIA3, 0.7 nM TNF, 10/zg/ml 
LPS, or 1 /~g/ml mouse recombinant IRAP. The culture media were 
then removed and analyzed for the formation of nitrite. Results are the 
average _ SEM of an individual experiment that is representative of two 
individual experiments. 
To confirm that TNF+LPS stimulate the release  of IL-1 
from nonendocrine islet cells, the effects of antisera specific 
for IL-13 and IL-lcz on nitrite formation by islets was exam- 
ined. As shown in Table 2, hamster anti-mouse IL-loe and 
IL-13 (1/~g/ml  for each antiserum)  attenuate TNF+LPS- 
induced nitrite formation by islets (Table 2). Consistent with 
the effects of IRAP, IL-1 antisera does not completely pre- 
vent TNF+LPS-induced nitrite formation, suggesting that 
TNF+LPS also induce the expression of iNOS in islet cells 
independent  of IL-1. 
Immunohistochemical Cellular Localization of  Insulin and iNOS. 
To directly determine the cellular source ofiNOS, the effects 
of IL-13, TNF+LPS, and TNF+LPS+IRAP on iNOS ex- 
pression  by  intact  islets  were  examined  by  immuno- 
histochemistry.  Rabbit antiserum specific for mouse macro- 
phage iNOS and guinea pig antiserum  specific  for human 
insulin were used to determine if iNOS expression localizes 
with insulin under the indicated conditions. In these experi- 
ments (Fig.  5), fluorescent secondary antisera used to stain 
iNOS and insulin were goat anti-rabbit CY3 (red), and donkey 
anti-guinea pig FITC (green), respectively.  IL-13 induces the 
expression of iNOS in nearly every insulin containing  cell 
(left column), as shown by the intense red staining of iNOS- 
containing cells which localizes with insulin (green)-containing 
cells (yellow on double exposure).  A few cells appear to 
stain for insulin that do not stain for iNOS (approximately 
four to five per islet) after IL-13 exposure, however we did 
not observe iNOS staining in the absence of insulin colocali- 
zation. TNF+LPS stimulate the expression ofiNOS in a lower 
percentage of islet cells (middle column) as compared with 
IL-13,  and TNF+LPS-induced  iNOS expression localizes 
predominately with insulin-containing fl cells (yellow). IRAP 
inhibits TNF+LPS-induced expression of iNOS in almost 
all of the insulin-containing 3 ceils (right column). Six cells 
stain positive for iNOS (red), and only one of these cells con- 
tains insulin (yellow cell located on the right edge of islet, 
bottom row of right column). The remaining five ceils posi- 
tive for iNOS are believed to be resident macrophages which 
comprise ~0.5% (10-15/islet) of all islet cells and are known 
to express  iNOS after treatment  with TNF+LPS (36,  37, 
39,  40, 41).  It is also possible that  these iNOS-containing 
cells could be endothelial or dendritic in origin.  Untreated 
control islets stain for insulin but iNOS staining was not ob- 
served (data not shown). Also, cross-reactivity of second an- 
tibodies with the tissue or with nonspecific antisera of the 
same species  as the primary  antiserum  was not  observed. 
TNF  + LPS Fail to Induce Nitrite Formation by Dispersed Islet 
Cells.  Results of Figs. 4 and 5 suggest that TNF+LPS stimu- 
late the release and accumulation of sufficient concentrations 
of IL-1 to induce the expression of iNOS by islet 3  cells. 
To further examine the potential role of local concentrations 
of cytokines, nitrite formation by intact islets was compared 
with nitrite formation from dispersed islet cells treated with 
IL-1 or TNF+ LPS. Dispersion of islets prevents the accumu- 
lation  of high  local  concentrations  of IL-1  by physically 
separating islets into single cells. In this experiment, IL-13 
stimulates a twofold increase in nitrite production by both 
islets and dispersed islet cells, and nitrite formation is com- 
pletely prevented by coincubation with 1/zg/ml IRAP (Fig. 
6). TNF+ LPS induce a 1.8-fold increase in nitrite formation 
by intact islets,  and this is also prevented by 1/zg/ml IRAP. 
Importantly,  TNF+LPS do not stimulate the formation of 
nitrite by dispersed islet cells. These results indicate that in 
intact islets,  TNF+LPS stimulate the release and accumula- 
tion of sufficient concentrations of IL-1 to induce the expres- 
sion ofiNOS by 3 cells. If islets are physically separated into 
single cells by dispersion, the concentration of IL-1 does not 
attain  sufficient levels to induce iNOS expression. 
Discussion 
IDDM is characterized by a local inflammatory reaction 
in the vicinity of islets that are undergoing autoimmune de- 
struction. Cytokines released during this inflammatory reac- 
tion have been proposed to participate in the destruction of 
cells (5). In this study we have used an in vitro approach 
Figure  5.  Immunohistochemical  localization of iNOS and insulin. Islets were incubated for 24 h with 5 U/ml 1I.-13, 0.7 nM TNF (7"), 10 #g/ml 
LPS (L), or I gtg/ml human recombinant IRAP as indicated. The islets were then isolated, sectioned, and stained for both insulin (INS; 1:500 dilution 
of guinea pig anti-human insulin) and iNOS (1:500 dilution of rabbit anti-mouse macrophage iNOS). Insulin and iNOS were visualized with FITC- 
conjugated donkey anti-guinea pig, and CY3-conjugated donkey anti-rabbit IgG second antibodies, respectively.  Results are representative of two in- 
dividual experiments. 
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iNOS expression and 3  cell function.  Exposure of rat islets 
to TNF+LPS results in an inhibition of insulin secretion that is 
mediated by the intraislet release of IL-1. Although TNF+ LPS 
induce the expression of iNOS and the production of nitric 
oxide by nonendocrine islet cells, TNF+LPS directly, or in- 
directly by inducing the production of nitric oxide by nonen- 
docrine islet cells, do not appear to inhibit B cell function. 
TNF+LPS-induced inhibition  of insulin secretion is medi- 
ated by the intraislet release of IL-1 and subsequent expres- 
sion of iNOS by islet 3  cells.  These results are contrary to 
the hypothesis of Kolb, Kolb-Bachofen and co-workers (42-44) 
who suggest that nitric oxide production by nonendocrine 
islet cells mediates cytokine-induced inhibition of islet func- 
tion.  Our results indicate that nonendocrine production of 
nitric  oxide may contribute to TNF+LPS-induced  inhibi- 
tion of insulin secretion, but this production of nitric oxide, 
per se, is not sufficient to inhibit insulin secretion by islets. 
These studies also support the concept that local release 
of cytokines in an islet markedly influence 3  cell function. 
TNF+ LPS stimulate nitrite formation by islets, but this com- 
bination does not induce nitrite formation by dispersed islet 
cells. Dispersion of islets into single cells prevents IL-1 from 
attaining  sufficient local concentrations  required  to induce 
iNOS expression by the 3 cell. This finding provides the first 
experimental  evidence demonstrating  that  it is possible to 
attain  intraislet  concentrations  of IL-1  sufficient  to induce 
iNOS expression and impair 3  cell function.  These results 
also have implications for the regulation of iNOS expression 
during conditions of infection, inflammation,  and transplan- 
tation rejection. The ability of cytokines to regulate the ex- 
pression of iNOS in local areas of inflammation  and infec- 
tion  suggest that  nitric  oxide may participate  as a specific 
effector molecule regulated at the level of expression by cyto- 
kine release  at  sites  of inflammation  or injury. 
Animal models of IDDM have shown that macrophages 
and monocytes are two of the first cells to infiltrate islets under 
autoimmune  attack and this is followed by the appearance 
of T cells (1-3). In an activated state these cell types are known 
to release IL-1, TNF, and IFN-% We have shown that NOD 
mouse islets produce nitric oxide in a time-dependent manner 
that precedes the development of diabetes (22).  The results 
of the current study suggest that during this immune attack 
the release  of cytokines in and around islets results in the 
generation of local concentrations of these cytokines sufficient 
for the expression ofiNOS by 3 cells. The induction ofiNOS 
in mouse and human  islets appears to require IL-1 and an 
additional signal, either IFN-v or TNF, whereas IL-1 alone 
is sufficient to induce iNOS in rat islets (17, 45, and our un- 
published observations). Recently we have shown that IRAP 
and antibodies specific for IL-loe and IL-13 inhibit the produc- 
tion of nitric oxide by mouse islets treated with TNF and 
IFN-3'  (our  unpublished  observations),  mRNA  for these 
cytokines have been demonstrated in NOD mouse islets un- 
dergoing autoimmune attack (46). These preliminary findings 
provide further support of the potential importance of local 
cytokine release and the induction of iNOS in the pathogen- 
esis of autoimmune  diabetes. 
Nitric oxide appears to participate in the inhibition of 
cell function, 3 cell destruction, and in the inflammatory re- 
sponse observed during the development of diabetes. IL-13 
induces the coexpression of inducible cyclooxygenase (COX-2) 
and iNOS by islets, and nitric oxide directly activates COX-2 
resulting in the production of proinflammatory prostaglandins 
(31,  47).  These findings  suggest that  local release  of cyto- 
kines may influence both the inflammatory response stimu- 
lated by the induction of COX-2,  and cellular destruction 
resulting from the expression of iNOS and the production 
of nitric  oxide. 
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